Year

Category

2023-05-26

Kancera appoints Peter Selin as new Chief Executive Officer

Kancera AB (publ) today announces that Peter Selin is appointed as new Chief Executive Officer (CEO) as of July 1 2023. At the same time, Thomas Olin is appointed as Executive Vice President and Chief Scientific Officer (CSO).

Read More
2023-05-19

Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

The period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...

Read More
2023-04-26

Kancera reports start of patient screening for the KANDOVA-study

Kancera today reports that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the Fractalkine blocker KAND567 in ovarian cancer patients, has been started at the Karolinska University Hospital.

Read More
2023-04-24

Kancera has submitted application to conduct First-In-Human study of KAND145

Kancera today reports that the company has submitted the regulatory application to conduct a First-In-Human study of its Fractalkine blocker KAND145.

Read More
2023-03-21

The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145

Kancera AB (publ) today reports that the Japan patent office has issued a patent that protects the manufacturing processes for Kancera’s Fractalkine blocking drug candidates KAND567 and KAND145.

Read More